{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:01:47Z","timestamp":1793314907319,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtho.2026.103643","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T13:13:44Z","timestamp":1775308424000},"page":"103643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee"],"prefix":"10.1016","author":[{"given":"Ryan A.","family":"McMahon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lee Min Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie P.L.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Munoz-Schuffenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsidhar","family":"Velcheti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.103643_bib1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.21.01719","article-title":"Practical management of oligometastatic non-small-cell lung cancer","volume":"40","author":"Jasper","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.jtho.2026.103643_bib3","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2026.103643_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","article-title":"Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de Novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial","volume":"6","author":"You","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41586-023-05729-x","article-title":"The evolution of non-small cell lung cancer metastases in TRACERx","volume":"616","author":"Al Bakir","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2026.103643_bib6","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/1754-9485.13096","article-title":"Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer","volume":"64","author":"Attia","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib7","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/s41598-021-81666-x","article-title":"Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients","volume":"11","author":"Heo","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2026.103643_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107427","article-title":"Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): a Swiss cohort study","volume":"187","author":"Schuler","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103643_bib9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.23.02075","article-title":"Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: a multicenter, randomized, controlled, phase III trial","volume":"43","author":"Sun","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib10","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2026.103643_bib11","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s00432-021-03831-z","article-title":"Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study","volume":"148","author":"Wei","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2026.103643_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib14","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, Phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib15","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.ijrobp.2023.06.352","article-title":"A multicentered, randomized phase III study of definitive vs. palliative radiotherapy to primary tumor for stage IV non-small cell lung cancer with less than three metastatic organs: CSWOG China","volume":"117","author":"Jie","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2026.103643_bib16","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.103643_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000867","article-title":"Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy","volume":"8","author":"Buchwald","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2026.103643_bib18","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/07357907.2013.767342","article-title":"Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer","volume":"31","author":"Campian","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.jtho.2026.103643_bib20","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2026.103643_bib21","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103643_bib22","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103643_bib23","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103643_bib24","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103643_bib25","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103643_bib26","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib27","article-title":"65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N \u00b1 ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC","volume":"24","author":"Peters","year":"2024","journal-title":"Immunooncol Technol"},{"key":"10.1016\/j.jtho.2026.103643_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13014-020-01730-0","article-title":"Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the \u2018TOaSTT\u2019 database","volume":"16","author":"Kroeze","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib29","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1001\/jamaoncol.2023.3309","article-title":"Durvalumab plus concurrent radiotherapy for treatment of locally advanced non-small cell lung cancer: the DOLPHIN phase 2 nonrandomized controlled trial","volume":"9","author":"Tachihara","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib30","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib32","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2025.43.16_suppl.8003","article-title":"SWOG\/NRG S1914: randomized phase III trial of induction\/consolidation atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC","volume":"43","author":"Simone","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib33","article-title":"117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I\/II non-small cell lung cancer (NSCLC). The randomized, double-blind, phase III KEYNOTE-867 study","volume":"24","author":"Pircher","year":"2024","journal-title":"Immunooncol. Technol"},{"key":"10.1016\/j.jtho.2026.103643_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432516","article-title":"New treatment options for patients with oncogene-addicted non-small cell lung cancer focusing on EGFR-mutant tumors","volume":"44","author":"Saw","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtho.2026.103643_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.01.005","article-title":"Interactions between EGFR and PD-1\/PD-L1 pathway: implications for treatment of NSCLC","volume":"418","author":"Li","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jtho.2026.103643_bib36","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.3390\/cancers13194780","article-title":"Continued versus interrupted targeted therapy during metastasis-directed stereotactic radiotherapy: a retrospective multi-center safety and efficacy analysis","volume":"13","author":"Kroeze","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2026.103643_bib37","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0167-8140(23)08772-8","article-title":"PD-0064 metastases-directed SRT combined with systemic therapy: 2y results of the TOaSTT real-world database","volume":"182","author":"Kroeze","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib38","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103643_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.aaf2784","article-title":"Metastasis as an evolutionary process","volume":"352","author":"Turajlic","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jtho.2026.103643_bib40","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/annonc\/mdx182","article-title":"Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient","volume":"28","author":"Ferronika","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib41","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/2159-8290.CD-15-0120","article-title":"Pancreatic cancer metastases harbor evidence of polyclonality","volume":"5","author":"Maddipati","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.103643_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2026.103643_bib43","doi-asserted-by":"crossref","first-page":"E854","DOI":"10.1073\/pnas.1508541113","article-title":"Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters","volume":"113","author":"Cheung","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2026.103643_bib44","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41588-019-0525-5","article-title":"The mutational footprints of cancer therapies","volume":"51","author":"Pich","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2026.103643_bib45","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1038\/s41467-021-24858-3","article-title":"The evolution of hematopoietic cells under cancer therapy","volume":"12","author":"Pich","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2026.103643_bib46","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated single cell seeding in relapsed multiple myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2026.103643_bib47","article-title":"Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring","volume":"120","author":"Li","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2026.103643_bib48","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.103643_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001429","article-title":"Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells","volume":"8","author":"Sun","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2026.103643_bib50","article-title":"The role of CD8 PET imaging in guiding cancer immunotherapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426000961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426000961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T13:13:49Z","timestamp":1775308429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426000961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"alternative-id":["S1556086426000961"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103643","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"103643"}}